PT-LODER FOR PROSTATE CANCER
· Prostate cancer is a cancer that forms in tissues of the prostate and usually occurs in older men. It is the third most common cause of death from cancer in men of all ages and is the most common cause of death from cancer in men over the age of 75. The American Cancer Society’s estimates for the number of new cases and deaths from prostate cancer in the United States in 2020 are 191,930 and 33,330, respectively.
Silenseed is employing the LODER platform in the treatment of prostate cancer. In pre-clinical in-vitro and in-vivo studies we have identified several targets, among which are the factors HSP90 and BMI1.
Hsp90 (Heat shock protein 90) is a molecular chaperone that regulates the maturation, activation, and stability of critical signalling proteins that drive the development and progression of prostate cancer, including androgen receptor signalling. Therefore, treatments that target Hsp90 would simultaneously disrupt multiple pathways in prostate cancer.
BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1) is a known stem cell marker that belongs to the Polycomb group transcriptional repressor family. BMI1 and another Polycomb group family member, enhancer of zeste homolog 2 (EZH2), have been implicated in regulating the prostate cancer stem cell phenotype. Bmi-1 was reported to be a crucial regulator of self-renewal in adult prostate cells and to play important roles in prostate cancer initiation and progression.
Silenseed is studying these candidates as they may have the potential to pose a new and competitive treatment for prostate cancer, specifically aimed at the long periods of local disease. PT-LODER may either compete with, or complete the current treatments, which included radiotherapy, surgery, cryosurgery, and hormonal therapies.